What is claimed is:

1. Use of a composition comprising at least one of guggulsterone, kynurenic acid, or kenpaullone in the manufacture of a medicament~~A method~~ for the prevention or treatment of Parkinson's disease (PD), the prevention or treatment comprising administering to a subject in need thereof a therapeutically effective amount of ~~at least one of guggulsterone, kynurenic acid, or kenpaullone~~said composition.

2. The ~~method~~ use of claim 1, wherein guggulsterone is administered orally or by injection.

3. The ~~method~~ use of claim 1, wherein guggulsterone is administered intravenously.

4. Use of a composition comprising at least one of guggulsterone, kynurenic acid, or kenpaullone in the manufacture of a medicament~~A method~~ for the prevention of ~~preventing~~ progression of PD, the prevention comprising administering to a subject in need thereof a therapeutically effective amount of ~~at least one of guggulsterone, kynurenic acid, or kenpaullone~~said composition.

5. The ~~method~~ use of claim 4, wherein guggulsterone is administered orally or by injection.

6. The ~~method~~ use of claim 4, wherein guggulsterone is administered intravenously.

7. Use of a composition comprising at least one of guggulsterone, kynurenic acid, or kenpaullone in the manufacture of a medicament~~A method~~ for the modulation of ~~modulating~~ dopaminergic neuronal activity in a subject in need thereof, the modulation comprising contacting dopaminergic neurons with ~~at least one of guggulsterone, kynurenic acid, or kenpaullone~~said composition, thereby modulating dopaminergic neuronal activity.

8. The ~~method~~ use of claim 7, wherein the dopaminergic neuronal activity is promoted or increased.

9. The ~~method~~ use of claim 7, wherein the dopaminergic neuronal activity is neuron function, neuron survival, or neurite outgrowth.

10. The ~~method~~ use of claim 7, wherein dopamine release is increased or stimulated.

11. The ~~method~~ use of claim 7, wherein the subject is suffering from a neurodegenerative disease or disorder.

12. The ~~method~~ use of claim 11, wherein the disease or disorder is non-viral encephalopathy, Parkinson's disease (PD), Alzheimer's disease (AD), amyotrophic

lateral sclerosis (ALS), Huntington's disease, multiple sclerosis (MS), a rare genetic disease, aging, or physical or ischemic injury of the nervous system.

13. The ~~method~~ use of claim 12, wherein the physical or ischemic injury of the nervous system is seizure, stroke, trauma, or epilepsy.